Mobile devices today have become ubiquitous, and tech companies are not the only ones trying to profit from this trend. Drugmakers have also started to catch on to the power of marketing through smartphones. Sanofi (SNY -0.92%), a leading provider of long-acting diabetes medications, was one of the first movers in this space and has a blood glucose monitor that works with iPhones.
Today, obesity drugmaker VIVUS (VVUS) announced that it is also getting in on this emerging trend. In an effort to further entice patients to try its obesity medication, Qsymia, VIVUS has announced a new mobile app that can help patients comply with their treatment. Health care analyst Max Macaluso discusses this story -- and what it means for investors -- in the following video.
